- Home
- RERE vs CBLL Comparison
RERE vs CBLL Comparison
Compare RERE & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- CBLL
- Stock Information
- Founded
- RERE 2011
- CBLL 2014
- Country
- RERE China
- CBLL United States
- Employees
- RERE N/A
- CBLL N/A
- Industry
- RERE Other Specialty Stores
- CBLL
- Sector
- RERE Consumer Discretionary
- CBLL
- Exchange
- RERE Nasdaq
- CBLL Nasdaq
- Market Cap
- RERE 678.4M
- CBLL 698.0M
- IPO Year
- RERE 2021
- CBLL 2024
- Fundamental
- Price
- RERE $2.97
- CBLL $18.77
- Analyst Decision
- RERE
- CBLL Strong Buy
- Analyst Count
- RERE 0
- CBLL 5
- Target Price
- RERE N/A
- CBLL $33.25
- AVG Volume (30 Days)
- RERE 924.1K
- CBLL 164.4K
- Earning Date
- RERE 03-11-2025
- CBLL 05-14-2025
- Dividend Yield
- RERE N/A
- CBLL N/A
- EPS Growth
- RERE N/A
- CBLL N/A
- EPS
- RERE N/A
- CBLL N/A
- Revenue
- RERE $2,237,042,920.00
- CBLL $65,444,000.00
- Revenue This Year
- RERE $27.18
- CBLL $30.47
- Revenue Next Year
- RERE N/A
- CBLL $29.61
- P/E Ratio
- RERE N/A
- CBLL N/A
- Revenue Growth
- RERE 25.93
- CBLL 44.71
- 52 Week Low
- RERE $1.50
- CBLL $18.50
- 52 Week High
- RERE $3.70
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- RERE 45.19
- CBLL N/A
- Support Level
- RERE $2.86
- CBLL N/A
- Resistance Level
- RERE $3.24
- CBLL N/A
- Average True Range (ATR)
- RERE 0.18
- CBLL 0.00
- MACD
- RERE -0.05
- CBLL 0.00
- Stochastic Oscillator
- RERE 16.92
- CBLL 0.00
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.